Literature DB >> 28612598

Relationship between Breast Cancer and Oral Contraceptivezzm321990Use among Thai Premenopausal Women: a Case-Control Study

Wisit Chaveepojnkamjorn1, Natchaporn Pichainarong, Rungsinoppadol Thotong, Pratana Sativipawee, Supachai Pitikultang.   

Abstract

Background: Breast cancer (BC) is an important issue both in medicine and public health as it is the leading malignancy with high incidence and mortality among women worldwide. The objective of this research was to determine the associations of BC with oral contraceptive (OC) use among Thai premenopausal women (TPW). Materials and
Methods: A case-control study was conducted among TPW attending the National Cancer Institute, with 257 cases and 257 controls in 2013-2014. Cases and controls were matched by age (± 5 years), residential area and duration of attendance. Data were collected with a questionnaire that comprised 2 sections: part 1 socio-demographic characteristics, and part 2 health risk behavior and reproductive factors. The obtained data were analyzed using descriptive and analytic statistics with a computerized statistical package.
Results: The study participants were mainly 40-44 years old (60 %) with an average age of 39 years. The major BC type was invasive ductal carcinoma (91.8%). Multiple unconditional logistic regression analysis, controlling for possible confounding factors, revealed that TPW with OC use increased the risk of BC by a factor of over 3 times (ORadj=3.39, 95%CI =1.99-5.75). In addition, the greater the duration of OC, the greater the risk (ORadj 6-10 yrs=3.91, 95%CI = 1.99-7.64, ORadj >10 yrs=4.23, 95%CI = 2.05-8.71). Conclusions: From our findings, a surveillance system of cancer risk with OC use should be conducted, accompanied by an exercise promotion campaign among risk groups, providing information and counseling for physical exercise and physical activities, weight control and basic adjustment for a healthy lifestyle to reduce BC. Creative Commons Attribution License

Entities:  

Keywords:  Breast cancer; oral contraceptive use; Thai premenopausal women

Year:  2017        PMID: 28612598      PMCID: PMC5555558          DOI: 10.22034/APJCP.2017.18.5.1429

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


Introduction

Cancers are the top leading cause of death. According to estimates of The World Health Organization (WHO), approximately 8.2 million cancer deaths occurred in 2014 and mortality mainly occurred in developing countries. Of these, 3.4 million are male and female 3.3 million. Almost 70 % of all cancers was seen in underdeveloped and developing countries (Siegel et al., 2015). At present, it is well established that BC is the most commonly diagnosed invasive cancer and the leading cause of cancer death among women worldwide including in Thailand (Siegel et al., 2015; National Cancer Control Committee, 2013; Bureau of Policy and Strategies, 2011; Bureau of Policy and Strategies, 2015). Causes of being BC are likely to be multifactorial. Some studies found that OC use is one of the risk factors of BC (Soroush et al., 2016; Rosenberg et al., 2009). The association between OC use and BC risk has been examined in numerous studies, mainly in western countries. In Thailand, there are quite very few studies of this association among premenopausal women. The present study was carried out to assess the association between OC use and BC occurrence among TPW.

Materials and Methods

Study Design, Sample Size and Sampling Technique

A hospital based case-control study (1:1) was performed at the National Cancer Institute in Bangkok during November 2013 -December 2014 to determine the effect of OC use and BC risk among TPW. A total of 257 BC cases and 257 controls were included in the study. The cases were newly diagnosed with breast cancer by pathologists. The controls were healthy TPW who had annual health check-up. Cases and controls were matched (1:1) by age (±5 years), residential area and duration of attending. Of the 514 women were both premenopausal and aged <45 years at the time of study. Cases and controls used the same questionnaire to obtain data collection. The sample size was calculated by the formula (Lwanga and Lemeshows, 1991). Where Po = proportion of exposure in controls = 0.32 (Umpan, 2004); P1 = proportion of exposure in cases = 0.68 (Umpan, 2004); Zα/2 = 1.96 at α = 0.05; Zβ = 0.84 at β = 0.20; and P = 0.5. The calculated sample size in each group was at least 256.

Tool and Measurements

Data collection was obtained by interviewing the study subjects by researcher and trained research assistants. The questionnaire comprised socio-demographic factors, health risk behaviors, reproductive factors, obesity and cancer status. While BC information was collected by laboratory and pathological results, namely, TNM classification, stage of disease, hormone receptor test, and date of diagnosis with BC.

Variable definitions

Premenopausal women were defined as those still having menstrual cycles at the time of study.

Ethical Considerations

The study was reviewed and approved by the Ethics Committee for research of National Cancer Institute, Ministry of Public Health (148/2556) and the Ethics Committee for Research in Human Subjects of the Faculty of Public Health, Mahidol University (Ref No. MuPH 2014-090) and agreed with the Helsinki declaration. All participants participated in this study are on a voluntary basis. Informed consent to participate in the study was obtained from participants after providing sufficient information. Information was collected by a self-administered questionnaire with the help and supervision of research assistants. Confidentiality was well kept throughout the study using anonymous technique (respondents were identified by code numbers to ensure confidentiality and the results were analyzed as a whole).

Statistical Analyses

The data were analyzed with SPSS version 18 (IBM, NY, USA). Categorical variables were given as a frequency and percentage, crude odds ratio, 95 % Confidence Interval (CI) of OR and p-value. The numerical variables were expressed as mean, minimum and maximum, and standard deviation (SD). Univariate analysis was performed using the chi-square test to differentiate proportional exposures between BC patents and controls for categorical variables. Adjusted odds ratio and the 95 % CI of OR were calculated from multiple unconditional logistic regression to examine associations between BC occurrence and BMI, adjusted for potential confounding factors of reproductive factors and health risk behaviors. A p-value of < 0.05 was considered to be statistically significant.

Results

Demographic Characteristics of Cases and Controls

A total of 514 TPW participated in the case-control study (1:1). The average age of subjects was 39 years. Table 1 outlines the socio-demographic characteristics of them. To summarize majority of them were aged 40-44 years (59.9%, 61.1%), married (61.8%, 60.7%), higher education (39.7%, 51.4%), buddhism (96.5%, 96.1%), living in central region (68.5%), office employee (35.8%, 33.8%), and had monthly family income of 15,000-30,000 baht (53.7%, 48.2%). There was no significant difference regarding demographics among cases and controls (p>0.05).
Table 1

General Characteristics of Cases and Controls

CharacteristicsCases No.%Controls No.%p value[a]
Age gr. (yrs)0.981
  ≤ 29103.9114.3
  30-343011.72810.9
  35-396324.56123.7
  40-4415459.915761.1
Mean (SD)39.20 (4.39)39.30 (4.41)
Min-Max25-4425-44
Marital status0.07
  Single6826.58432.7
  Married15961.815660.7
  Widowed/Divorced3011.7176.6
Education0.068
  No formal education103.983.1
  Primary school6726.15220.2
  Secondary school7830.36525.3
  Higher education10239.713251.4
Religion0.689
  Buddhism24896.524796.1
  Islam72.762.3
  Christianity20.841.6
Residence1
  North10.410.4
  Northeast114.3114.3
  Central17668.517668.5
  East166.2166.2
  West4818.74818.7
  South51.951.9
Occupation0.668
  Office employee9235.88733.8
  Entrepreneur77308533.1
  Government officer7328.47529.2
  Agriculture155.8103.9
Monthly family income (baht)0.066
  < 10,0003814.83413.2
  10,000-15,0005220.24818.7
  15,001-30,00013853.712448.2
  >30,0002911.35119.9
Mean(SD)22,740.08 (9,311.92)24,174.32 (13,541.38)
Min-Max7,000-70,0007,800-95,000

chi-square test

General Characteristics of Cases and Controls chi-square test

BC and Risk Factors

Using a univariate analysis, we found that risk factors of developing BC among TPW were family history of BC, history of benign breast tumor, younger age at menarche, parity, miscarriage, OC use, passive smoking, multivitamin use and BMI (p<0.05) as shown in Table 2. Using a multiple unconditional logistic regression analysis, OC use showed the association with BC occurrence after controlling for possible confounding factors (family history of BC, history of benign breast tumor, younger age at menarche, parity, miscarriage, BMI, passive smoking, and multivitamin use). Risk of developing BC with OC use was 3.39 and times (ORadj= 3.39, 95%CI=1.99-5.75), When considering the duration of OC use, the more exposed, the more being BC (ORadj 6-10 yrs=3.91, 95%CI = 1.99-7.64, ORadj >10 yrs=4.23, 95%CI = 2.05-8.71) as shown in Table 3.
Table 2

Crude Analysis of Characteristics associated with BC among TPW

CharacteristicsCases No.%Controls No.%ORc95%CIp-value[a]
Family history of BC
  No21182.124996.91.00
  Yes4617.983.16.793.13-14.69< 0.001*
History of benign breast tumor
  No20981.323591.31.00
  Yes4818.7228.62.451.43-4.200.001*
Age at menarche (yrs)
  ≥148332.314054.51.00
  <1417467.711745.52.511.75-3.59< 0.001*
Parity
  No19375.117266.91.00
  Yes6424.98533.10.670.45-0.990.041*
Miscarriage
  No18672.421483.31.00
  Yes7127.64316.71.901.21-2.980.003*
OC use
  No903516263.01.00
  Yes167659537.03.162.21-4.54< 0.001*
Duration of OC use (yrs)
  0903516263.01.00
  1-54216.34417.11.721.01-2.900.031*
  6-107027.23011.74.22.48-7.17< 0.001*
  >105521.5218.24.712.59-8.72< 0.001*
Active smoking
  No24896.525197.71.00
  Yes93.562.31.520.53-4.330.432
Passive smoking
  No15359.519877.11.00
  Yes10440.55922.92.281.53-3.41< 0.001*
Alcohol consumption
  No25197.725298.11.00
  Yes62.351.91.200.32-4.610.761
Multivitamin use
  No22788.316865.41
  Yes3011.78934.60.250.15-0.40< 0.001*
Body mass index (kg/m2)
  18.5-22.98934.712247.41.00
  23.0-24.94417.15421.01.120.67-1.860.629
  25.0-29.98834.24116.02.941.81-4.79< 0.001*
  ≥30.02610.1103.93.561.55-8.38< 0.001*
  <18.5103.93011.70.460.20-1.050.056

chi-square test, ORc= crude odds ratio, CI= confidence interval;

significant at p-value <0.05.

Table 3

Multivariable Logistic Regression Analysis of OC use associated with BC among TPW

VariablesORc95%CIORadj95%CIp-value
OC use
  No11
  Yes3.162.21-4.543.391.99-5.75<0.001*
Duration of OC use (yrs)
  011
  1-51.721.01-2.901.720.90-3.250.099
  6-104.22.48-7.173.911.99-7.64<0.001*
  >104.712.59-8.724.232.05-8.71<0.001*

ORc, crude OR; ORadj, adjusted OR for family history of BC; history of benign breast tumor, age at menarche, parity, miscarriage, passive smoking, multivitamin use and BMI;

significant at p-value <0.05

Crude Analysis of Characteristics associated with BC among TPW chi-square test, ORc= crude odds ratio, CI= confidence interval; significant at p-value <0.05. Multivariable Logistic Regression Analysis of OC use associated with BC among TPW ORc, crude OR; ORadj, adjusted OR for family history of BC; history of benign breast tumor, age at menarche, parity, miscarriage, passive smoking, multivitamin use and BMI; significant at p-value <0.05

BC Patients’ Characteristics

Cases were newly patients with BC diagnosed by pathological confirmation and laboratory testing during November 2013-December 2014. Majority of them were 55-64 kg (40.5%) and 150-159 cm (65.7%). Focusing on body size, 60.7% showed obesity and overweight. Location of BC, mostly in both sides (52.2%). Most of study cases were IDC-NOS (91.8%), stage II (45.5%). For OC use group, duration for OC use, mostly 6-10 yr. (41.9%).

Discussion

Study participants were the TPW, mostly aged 40-44 years (60%). Socio-demographic characteristics of cases and controls were quite alike. When controlled by health risk behaviors and reproductive factors, found that TPW with OC use was being BC risks. Our findings indicated that women with OC use were about 3 times risk to develop BC. It was consistent with the previous studies (Soroush et al., 2016; Rosenberg et al., 2009; Nyante et al., 2008; Kahlenborn et al., 2006; Newcomer et al., 2003; Hemminki et al., 2002; Grabrick et al., 2000), meanwhile some studies showed the contrary results (Haile et al., 2006; Silvera et al., 2005; Mine et al., 2005; Jernstrom et al., 2005; Tessaro et al., 2001; Van Hoften et al., 2000). The reason to support the association owing to estrogen hormone in OC pills, therefore it will have a cohesion with specific receptor on cancer cell’s surface and then it will send the biochemical signals and activate cell multiplication (Howlader et al., 2016). The association had no evidence in OC use with only progesterone (McNaught et al., 2006). In addition, the present studies revealed the risk of BC had increased according to duration of OC use and it’s consistent with some studies (Howlader et al., 2016; Collaborative Group on Hormonal Factors in Breast Cancer, 1996). Therefore, birth control with BC patients should be namely, contraceptive pills with progesterone, depot medroxyprogesterone acetate injection, intrauterine device (IUD) with progesterone, and so on (Kabos and Borges, 2011). In addition, breast self examination is very necessary, so women should be done correctly (Smith et al., 2003). For women ≥ 40 years should be checked up with mammogram annually (Smith et al., 2003; American College of Radiology, 2013). There are a lot of tools for BC risk evaluation, such as the Gail Model, the Claus Model, the Tyree-Cuzick Model and the BRCAPRO model (Santen et al., 2007; Hollingsworth et al., 2004). For Thais, campaign of women aged ≥ 20 years to examine by themselves, they should be aware of advantages and limitations of this technique, support breast feeding after give birth 6 months, reduce alcohol consumption and reduce obesity (National Cancer Control Committee, 2013). Therefore, the surveillance of cancer risk and contraceptive use is the crucial measure to reduce BC risks.

Advantages and limitation of the Study

There are some advantages of this case-control study. First, the National Cancer Institute is the specialized hospital for cancer patients. Second, they are easily identified, and provide sufficient numbers. Finally, cases are newly BC patients diagnosed and confirmed by pathologists, which lead to the reduction in classification bias. Some limitations of this study should be noted. First, the study was a hospital based case-control study, therefore, the representative of target population couldn’t be mentioned. Second, it was very difficult to select the suitable controls. However, we matched cases and controls by age, residence and duration of attending. In summary, it should be the surveillance system of cancer risks and OC use and campaign of cancer prevention such as proper exercise, healthy diet, weight control and basic methods for health lifestyle among risk groups (National Cancer Control Committee, 2013), it will minimize and reduce risks of developing BC.
  19 in total

1.  Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.

Authors:  D M Grabrick; L C Hartmann; J R Cerhan; R A Vierkant; T M Therneau; C M Vachon; J E Olson; F J Couch; K E Anderson; V S Pankratz; T A Sellers
Journal:  JAMA       Date:  2000-10-11       Impact factor: 56.272

2.  American Cancer Society guidelines for breast cancer screening: update 2003.

Authors:  Robert A Smith; Debbie Saslow; Kimberly Andrews Sawyer; Wylie Burke; Mary E Costanza; W Phil Evans; Roger S Foster; Edward Hendrick; Harmon J Eyre; Steven Sener
Journal:  CA Cancer J Clin       Date:  2003 May-Jun       Impact factor: 508.702

3.  Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.

Authors:  Helena Jernström; Niklas Loman; Oskar T Johannsson; Ake Borg; Håkan Olsson
Journal:  Eur J Cancer       Date:  2005-08-22       Impact factor: 9.162

4.  Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.

Authors:  Roger L Milne; Julia A Knight; Esther M John; Gillian S Dite; Ronald Balbuena; Argyrios Ziogas; Irene L Andrulis; Dee W West; Frederick P Li; Melissa C Southey; Graham G Giles; Margaret R E McCredie; John L Hopper; Alice S Whittemore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

5.  Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.

Authors:  Chris Kahlenborn; Francesmary Modugno; Douglas M Potter; Walter B Severs
Journal:  Mayo Clin Proc       Date:  2006-10       Impact factor: 7.616

6.  Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort.

Authors:  C Van Hoften; H Burger; P H Peeters; D E Grobbee; P A Van Noord; H G Leufkens
Journal:  Int J Cancer       Date:  2000-08-15       Impact factor: 7.396

7.  [Oral contraceptive and breast cancer: a case-control study].

Authors:  S Tessaro; J U Béria; E Tomasi; A J Barros
Journal:  Rev Saude Publica       Date:  2001-02       Impact factor: 2.106

8.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

9.  The association between oral contraceptive use and lobular and ductal breast cancer in young women.

Authors:  Sarah J Nyante; Marilie D Gammon; Kathleen E Malone; Janet R Daling; Louise A Brinton
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

10.  Oral contraceptive use and risk of breast cancer by histologic type.

Authors:  Laura M Newcomer; Polly A Newcomb; Amy Trentham-Dietz; Matthew P Longnecker; E Robert Greenberg
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

View more
  1 in total

1.  Body Mass Index and Breast Cancer Risk among Thai Premenopausal Women: a Case-Control Study

Authors:  Wisit Chaveepojnkamjorn; Rungsinoppadol Thotong; Pratana Sativipawee; Supachai Pitikultang
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.